Photo of Samuel Waxman

Samuel Waxman

  • DISTINGUISHED SERVICE PROFESSOR Medicine, Hematology and Medical Oncology
  • DISTINGUISHED SERVICE PROFESSOR Oncological Sciences
Print ProfilePrint Profile

Certifications

  • Hematology

  • American Board of Internal Medicine

Education

  • MD, S.U.N.Y., Health Science Center

  • Residency, Internal Medicine
    Mount Sinai Hospital

  • Residency, Internal Medicine
    Mount Sinai Hospital

  • Fellowship, Hematology
    Mount Sinai Hospital

Biography

    A valued member of Mount Sinai's faculty for over 30 years, Samuel Waxman is the Zena and Michael A. Wiener Professor of Medicine (Cancer). Dr. Waxman currently holds a variety of positions, including Professor Consultant, Shanghai Second Medical University, Head, Rochelle Belfer Chemotherapy Foundation Laboratory in the Division of Medical Oncology at The Mount Sinai Medical Center, and Medical Director, Samuel Waxman Cancer Research Foundation.

Publications

Ferrari AC, Waxman S. Differentiation Agents in Cancer Therapy. In: Pinedo HM, Longo DL, Chabner BA, editors. Cancer Chemotherapy and Biological Response Modifiers Annual 15. B.V., Elsevier Science; 1994.

Jing Y, Zhang J, Bleiweiss IB, Waxman S, Zelent A, Mira-Y-Lopez R . Defective expression of cellular retinol binding protein type I and retinoic acid receptors a2, b2, and g2 in human breast cancer cells. FASEB J 1996; 10: 1064-1070.

Jing Y, Waxman S, Mira-Y-Lopez R . The cellular retinoic acid binding protein II is a positive regulator of retinoic acid signaling in breast cancer cells. Cancer Res 1997; 57: 1668-1672.

Dai J, Weinberg R, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999; 93: 268-277.

Waxman S. Differentiation therapy in acute myelogenous leukemia (non-APL). Leukemia 2000; 14: 491-496.

Huang Y, Waxman S. Regrowth of 5-fluorouracil treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin and phenylbutyrate. Cancer Research 2000; 60: 3200-3206.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Waxman did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central

Address

1150 Fifth Avenue
New York, NY 10128

Tel: 212-289-2828
Fax: 212-860-9134
Get Directions

Office Hours:
  • Tuesday 8:00am - 3:00pm
Insurance Plans
  • Medicare Assignment
Payment Methods
  • Master Card
  • Visa
  • American Express
  • Personal Check
  • Cash